Vaccine-preventable diseases vaccines and Guillain-Barre syndrome.

Friday, 6th of July 2018 Print

Vaccine. 2018 Jun 4. pii: S0264-410X(18)30798-9. doi: 10.1016/j.vaccine.2018.05.119. [Epub ahead of print]

Vaccine-preventable diseases vaccines and Guillain-Barre syndrome.

Principi N1 Esposito S2.

 

Abstract

Guillain-Barré syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy. Infections and vaccines have been hypothesized to play a role in triggering GBS development. These beliefs can play a role in reducing vaccination coverage. In this report data concerning this hypothesis are discussed. It is shown that an association between vaccine administration and GBS has never been proven for most of debated vaccines although it cannot be definitively excluded. The only exception is the influenza vaccine at least for the preparation used in 1976. For some vaccines such as measles/mumps/rubella human papillomavirus tetravalent conjugated meningococcal vaccine and influenza the debate between supporters and opponents of vaccination remains robust and perception of vaccines low safety remains a barrier to achieving adequate vaccination coverage. Less than 1 case of GBS per million immunized persons might occur for these vaccines. However in some cases immunization actually reduces the risk of GBS development. In addition the benefits of vaccination are clearly demonstrated by the eradication or enormous decline in the incidence of many vaccine-preventable diseases. These data highlight that the hypothesized risks of adverse events such as GBS cannot be considered a valid reason to avoid the administration of currently recommended vaccines.

KEYWORDS:

Guillain-Barrè syndrome; Human papillomavirus vaccine; Influenza; Measles/mumps/rubella vaccine; Safety; Tetravalent conjugated meningococcal vaccine

PMID: 29880241 DOI: 10.1016/j.vaccine.2018.05.119

 

Special Postings

;

Highly Accessed

Website Views

2012875